Efficient Control of IL-6, CRP and Ferritin in COVID-19 Patients With Two Variants of Beta-1,3-1,6 Glucans in Combination: An Open-Label, Prospective, Randomised Clinical Trial
These results indicate that while co-supplementation with AFO-202 and N-163 beta-glucans led to improvement in CRP, ferritin, and IL-6 levels in COVID-19 patients, only the reduction in IL-6 levels on day 7 reached statistical significance. Further long-term multicentric clinical research is warranted to validate the potential of these supplements as treatment adjuncts, for addressing inflammation in COVID-19, especially in vulnerable populations infected with emerging SARS-CoV-2 variants.
Authors
- Ethirajan Theranirajan
- Doraisamy Sudhakar
- Samuel JK Abraham (ORCID: https://orcid.org/0000-0003-2646-2687)
- Sudha Seshayyan (ORCID: https://orcid.org/0000-0001-5007-9210)
- Senthilkumar Preethy (ORCID: https://orcid.org/0000-0002-9333-0361)
- Nobunao Ikewaki
- Subramanian Pushkala
- Kadalraja Raghavan
- Masaru Iwasaki (ORCID: https://orcid.org/0000-0003-3766-8744)
- Vidyasagar Devaprasad Dedeepiya
Institutions
- Kyushu University of Health and Welfare (JP)
- Faulkner University (US)
- Madras Medical College (IN)
- Society for Public Health Education (US)
- Tamil Nadu Dr. M.G.R. Medical University (IN)
- Government General Hospital (IN)
- Educational Research Institute (PL)
- Institute for Stem Cell Biology and Regenerative Medicine (IN)
- Global College (CY)
- MRC Centre for Regenerative Medicine (GB)
- GC Corporation (Japan) (JP)
- MemorialCare Health System (US)
- University of Yamanashi (JP)
Publication Details
- Journal
- Global Advances in Integrative Medicine and Health
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1177/27536130251327134
- Citations
- 3
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.19